platinum and mk-1775
platinum has been researched along with mk-1775 in 6 studies
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Brantley, SG; Cress, WD; Gray, JE; Haura, EB; Jhuraney, A; Kinose, F; Koomen, JM; Kroeger, JL; Monteiro, AN; Remily-Wood, E; Rix, L; Rix, U; Woods, NT; Wright, G | 1 |
| Ahn, JS; Ahn, MJ; Godin, RE; Hollingsworth, SJ; Jung, HA; Kim, HJ; Lee, SH; Mortimer, PGS; Park, K; Park, S; Park, WY; Shim, J; Smith, SA; Sun, JM | 1 |
| Blagden, SP; Nicum, S | 1 |
| Killock, D | 1 |
| Cadoo, KA; Chambers, SK; Chen, LM; Chmielecki, J; Cragun, JM; Geenen, JJJ; Ghamande, SA; Hamilton, EP; Jones, SF; Konecny, GE; Kumar, S; Lai, Z; Moore, KN; Mugundu, GM; Oza, AM; Plaxe, SC; Rodrigo Imedio, E; Spigel, DR; Spitz, DL; Troso-Sandoval, TA | 1 |
| Bowering, V; Chang, K; Dhani, NC; Karakasis, K; Kavak, N; Lheureux, S; Madariaga, A; Mitchell, SA; Oza, AM; Pittman, T; Quintos, J; Ramsahai, J; Wang, L; Welch, SA | 1 |
Trials
2 trial(s) available for platinum and mk-1775
| Article | Year |
|---|---|
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Drug-Related Side Effects and Adverse Reactions; Female; Gene Amplification; Humans; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Platinum; Progression-Free Survival; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Pyrimidinones; Rapamycin-Insensitive Companion of mTOR Protein; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2020 |
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian ca
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fatigue; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum | 2022 |
Other Studies
4 other study(ies) available for platinum and mk-1775
| Article | Year |
|---|---|
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Topics: Antineoplastic Agents; Apoptosis; Carrier Proteins; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cluster Analysis; Cyclin-Dependent Kinases; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Mitosis; Nuclear Proteins; Phosphorylation; Platinum; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones | 2016 |
A source of hope for platinum-resistant ovarian cancer?
Topics: Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Pyrazoles; Pyrimidinones | 2021 |
WEE1 inhibition after platinum resistance.
Topics: Cell Cycle Proteins; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones | 2021 |
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrazoles; Pyrimidinones | 2022 |